Key Points
- EVP Michael Feld sold 75 shares of Becton, Dickinson (BDX) on Feb. 26 at an average price of $181.84 for $13,638, leaving him with 21,308 shares (a 0.35% ownership decrease, valued ≈ $3.87M).
- The Feb. 26 sale continues a recent pattern of insider selling by Feld, who also sold 75 shares on Jan. 26 (at $202.73), 74 shares on Dec. 26 (at $196.08) and 75 shares on Dec. 1 (at $193.36).
- BDX recently beat Q4 expectations with $2.91 EPS vs. $2.81 estimated and $5.25B revenue vs. $5.15B, set FY‑2026 guidance of $12.35–12.65 EPS, declared a $1.05 quarterly dividend (2.4% yield) and authorized a $10M share buyback.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) EVP Michael Feld sold 75 shares of the company's stock in a transaction that occurred on Thursday, February 26th. The stock was sold at an average price of $181.84, for a total transaction of $13,638.00. Following the completion of the transaction, the executive vice president owned 21,308 shares of the company's stock, valued at approximately $3,874,646.72. The trade was a 0.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Michael Feld also recently made the following trade(s):
- On Monday, January 26th, Michael Feld sold 75 shares of Becton, Dickinson and Company stock. The shares were sold at an average price of $202.73, for a total transaction of $15,204.75.
- On Friday, December 26th, Michael Feld sold 74 shares of Becton, Dickinson and Company stock. The stock was sold at an average price of $196.08, for a total value of $14,509.92.
- On Monday, December 1st, Michael Feld sold 75 shares of Becton, Dickinson and Company stock. The shares were sold at an average price of $193.36, for a total value of $14,502.00.
Becton, Dickinson and Company Price Performance
Shares of NYSE:BDX traded down $0.62 during trading on Friday, hitting $176.04. 4,298,153 shares of the company's stock were exchanged, compared to its average volume of 3,165,117. The business's 50-day simple moving average is $195.68 and its 200 day simple moving average is $192.08. The company has a market cap of $50.12 billion, a price-to-earnings ratio of 28.72, a PEG ratio of 12.81 and a beta of 0.25. Becton, Dickinson and Company has a 52-week low of $127.59 and a 52-week high of $187.35. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.05 and a quick ratio of 0.58.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its quarterly earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 EPS for the quarter, topping the consensus estimate of $2.81 by $0.10. The business had revenue of $5.25 billion for the quarter, compared to analysts' expectations of $5.15 billion. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. The business's quarterly revenue was up 1.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $3.43 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. As a group, equities analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current year.
Becton, Dickinson and Company Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 31st. Investors of record on Tuesday, March 10th will be issued a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a yield of 2.4%. The ex-dividend date is Tuesday, March 10th. Becton, Dickinson and Company's dividend payout ratio is presently 68.52%.
Becton, Dickinson and Company declared that its Board of Directors has initiated a stock buyback plan on Tuesday, January 27th that allows the company to buyback $10.00 million in shares. This buyback authorization allows the medical instruments supplier to reacquire up to 0% of its stock through open market purchases. Stock buyback plans are usually a sign that the company's board of directors believes its shares are undervalued.
Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the company. Brighton Jones LLC boosted its holdings in Becton, Dickinson and Company by 98.2% in the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier's stock valued at $401,000 after purchasing an additional 877 shares during the last quarter. Empowered Funds LLC grew its stake in shares of Becton, Dickinson and Company by 20.4% during the 1st quarter. Empowered Funds LLC now owns 7,977 shares of the medical instruments supplier's stock worth $1,827,000 after purchasing an additional 1,354 shares during the period. United Bank lifted its stake in shares of Becton, Dickinson and Company by 23.9% in the 2nd quarter. United Bank now owns 5,149 shares of the medical instruments supplier's stock valued at $887,000 after purchasing an additional 993 shares during the period. Wealthfront Advisers LLC raised its position in shares of Becton, Dickinson and Company by 67.5% in the second quarter. Wealthfront Advisers LLC now owns 13,330 shares of the medical instruments supplier's stock worth $2,296,000 after acquiring an additional 5,370 shares during the period. Finally, Ashton Thomas Private Wealth LLC boosted its stake in shares of Becton, Dickinson and Company by 55.1% during the 2nd quarter. Ashton Thomas Private Wealth LLC now owns 4,838 shares of the medical instruments supplier's stock worth $833,000 after acquiring an additional 1,718 shares in the last quarter. 86.97% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of equities analysts recently issued reports on BDX shares. Royal Bank Of Canada set a $172.00 price objective on Becton, Dickinson and Company in a report on Tuesday, February 10th. Zacks Research lowered shares of Becton, Dickinson and Company from a "hold" rating to a "strong sell" rating in a research note on Wednesday, February 11th. Barclays started coverage on shares of Becton, Dickinson and Company in a research note on Tuesday, February 10th. They issued an "overweight" rating and a $202.00 price target on the stock. Stifel Nicolaus lifted their price objective on shares of Becton, Dickinson and Company from $210.00 to $215.00 and gave the company a "buy" rating in a report on Wednesday, January 7th. Finally, Morgan Stanley upped their target price on shares of Becton, Dickinson and Company from $197.00 to $210.00 and gave the stock an "overweight" rating in a research note on Tuesday, December 2nd. Five equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $195.46.
Get Our Latest Stock Analysis on BDX
About Becton, Dickinson and Company
(
Get Free Report)
Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.
BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
